Jay Lichter, Avalon BioVentures CEO

Aval­on Ven­tures spins off a sep­a­rate fund to han­dle life sci­ence com­pa­nies — armed with $135M

Aval­on Ven­tures has been a ma­jor play­er in the in­vest­ing games both in tech and in the biotech world, but now a new fund will be ze­roed in on in­vest­ing in the life sci­ence field.

Chris­tened Aval­on BioVen­tures, the ven­ture cap­i­tal firm will be com­mit­ted to in­vest­ing in ear­ly-stage bio­med­ical com­pa­nies and has of­fi­cial­ly closed the fund with $135 mil­lion on hand from new and ex­ist­ing in­vestors. The com­pa­ny will be fo­cused specif­i­cal­ly on the life sci­ence space on­ly and emerg­ing from Aval­on’s tech and life sci­ence ap­proach. The com­pa­ny will con­tin­ue to “lever­age” Aval­on’s team and ac­cel­er­a­tor; Aval­on founder Kevin Kin­sel­la will be brought in as an emer­i­tus part­ner.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA